Receptor, ErbB-2

"Receptor, ErbB-2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A cell surface protein-tyrosine kinase receptor that is overexpressed in a variety of ADENOCARCINOMAS. It has extensive homology to and heterodimerizes with the EGF RECEPTOR, the ERBB-3 RECEPTOR, and the ERBB-4 RECEPTOR. Activation of the erbB-2 receptor occurs through heterodimer formation with a ligand-bound erbB receptor family member.

Descriptor ID	D018719
MeSH Number(s)	D08.811.913.696.620.682.725.400.009.400 D12.776.543.750.630.009.400 D12.776.543.750.750.400.074.400 D12.776.624.664.700.642 D23.050.301.500.600.700 D23.050.705.552.600.550 D23.101.140.642
Concept/Terms	Receptor, ErbB-2 Receptor, ErbB-2 ErbB-2 Receptor Antigens, CD340 CD340 Antigens Proto-Oncogene Proteins c-erbB-2 Proto Oncogene Proteins c erbB 2 p185(c-neu) c-erbB-2 Protein c erbB 2 Protein erbB-2 Proto-Oncogene Protein Proto-Oncogene Protein, erbB-2 erbB 2 Proto Oncogene Protein erbB-2 Receptor Protein-Tyrosine Kinase erbB 2 Receptor Protein Tyrosine Kinase neu Proto-Oncogene Protein Proto-Oncogene Protein, neu neu Proto Oncogene Protein HER-2 Proto-Oncogene Protein HER 2 Proto Oncogene Protein Proto-Oncogene Protein, HER-2 Proto-Oncogene Protein HER-2 Proto Oncogene Protein HER 2 Receptors, erbB-2 erbB-2 Receptors Neu Receptor Receptor, Neu Metastatic Lymph Node Gene 19 Protein Proto-oncogene Protein Neu Neu, Proto-oncogene Protein Proto-oncogene c-ErbB-2 c-ErbB-2, Proto-oncogene Tyrosine Kinase-type Cell Surface Receptor HER2 Tyrosine Kinase type Cell Surface Receptor HER2 p185erbB2 Protein CD340 Antigen Oncogene Protein HER-2 Oncogene Protein HER 2 Proto-Oncogene Protein p185(neu)

Below are MeSH descriptors whose meaning is more general than "Receptor, ErbB-2".

Chemicals and Drugs [D]
Enzymes and Coenzymes [D08]
Enzymes [D08.811]
Transferases [D08.811.913]
Phosphotransferases [D08.811.913.696]
Phosphotransferases (Alcohol Group Acceptor) [D08.811.913.696.620]
Protein Kinases [D08.811.913.696.620.682]
Protein-Tyrosine Kinases [D08.811.913.696.620.682.725]
Receptor Protein-Tyrosine Kinases [D08.811.913.696.620.682.725.400]
ErbB Receptors [D08.811.913.696.620.682.725.400.009]
Receptor, ErbB-2 [D08.811.913.696.620.682.725.400.009.400]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Membrane Proteins [D12.776.543]
Receptors, Cell Surface [D12.776.543.750]
Receptor Protein-Tyrosine Kinases [D12.776.543.750.630]
ErbB Receptors [D12.776.543.750.630.009]
Receptor, ErbB-2 [D12.776.543.750.630.009.400]
Receptors, Peptide [D12.776.543.750.750]
Receptors, Growth Factor [D12.776.543.750.750.400]
ErbB Receptors [D12.776.543.750.750.400.074]
Receptor, ErbB-2 [D12.776.543.750.750.400.074.400]
Neoplasm Proteins [D12.776.624]
Oncogene Proteins [D12.776.624.664]
Proto-Oncogene Proteins [D12.776.624.664.700]
Receptor, ErbB-2 [D12.776.624.664.700.642]
Biological Factors [D23]
Antigens [D23.050]
Antigens, Surface [D23.050.301]
Histocompatibility Antigens [D23.050.301.500]
Minor Histocompatibility Antigens [D23.050.301.500.600]
Receptor, ErbB-2 [D23.050.301.500.600.700]
Isoantigens [D23.050.705]
Histocompatibility Antigens [D23.050.705.552]
Minor Histocompatibility Antigens [D23.050.705.552.600]
Receptor, ErbB-2 [D23.050.705.552.600.550]
Biomarkers [D23.101]
Biomarkers, Tumor [D23.101.140]
Receptor, ErbB-2 [D23.101.140.642]

Below are MeSH descriptors whose meaning is related to "Receptor, ErbB-2".

Below are MeSH descriptors whose meaning is more specific than "Receptor, ErbB-2".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Receptor, ErbB-2" by people in this website by year, and whether "Receptor, ErbB-2" was a major or minor topic of these publications.

Bar chart showing 42 publications over 21 distinct years, with a maximum of 4 publications in 2003 and 2004 and 2020

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1994	0	1	1
2001	1	0	1
2002	0	1	1
2003	3	1	4
2004	3	1	4
2005	0	1	1
2006	0	2	2
2007	0	1	1
2008	0	2	2
2009	1	1	2
2010	1	1	2
2011	0	3	3
2012	1	0	1
2013	1	0	1
2015	2	0	2
2016	1	2	3
2017	1	1	2
2018	1	0	1
2019	1	2	3
2020	2	2	4
2021	1	0	1

Below are the most recent publications written about "Receptor, ErbB-2" by people in Profiles.

Bundred N, Porta N, Brunt AM, Cramer A, Hanby A, Shaaban AM, Rakha EA, Armstrong A, Cutress RI, Dodwell D, Emson MA, Evans A, Hartup SM, Horgan K, Miller SE, McIntosh SA, Morden JP, Naik J, Narayanan S, Ooi J, Skene AI, Cameron DA, Bliss JM. Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results. Clin Cancer Res. 2022 Apr 01; 28(7):1323-1334.

View in: PubMed
Vranic S, Bešlija S, Gatalica Z. Targeting HER2 expression in cancer: New drugs and new indications. Bosn J Basic Med Sci. 2021 Feb 01; 21(1):1-4.

View in: PubMed
Naffar-Abu Amara S, Kuiken HJ, Selfors LM, Butler T, Leung ML, Leung CT, Kuhn EP, Kolarova T, Hage C, Ganesh K, Panayiotou R, Foster R, Rueda BR, Aktipis A, Spellman P, Ince TA, Xiu J, Oberley M, Gatalica Z, Navin N, Mills GB, Bronson RT, Brugge JS. Transient commensal clonal interactions can drive tumor metastasis. Nat Commun. 2020 11 16; 11(1):5799.

View in: PubMed
Parashar D, Nair B, Geethadevi A, George J, Nair A, Tsaih SW, Kadamberi IP, Gopinadhan Nair GK, Lu Y, Ramchandran R, Uyar DS, Rader JS, Ram PT, Mills GB, Pradeep S, Chaluvally-Raghavan P. Peritoneal Spread of Ovarian Cancer Harbors Therapeutic Vulnerabilities Regulated by FOXM1 and EGFR/ERBB2 Signaling. Cancer Res. 2020 12 15; 80(24):5554-5568.

View in: PubMed
Vranic S, Skenderi F, Beslagic V, Gatalica Z. Glycogen-rich Clear Cell Carcinoma of the Breast: A Comprehensive Review. Appl Immunohistochem Mol Morphol. 2020 10; 28(9):655-660.

View in: PubMed
Battisti NML, Rogerson F, Lee K, Shepherd S, Mohammed K, Turner N, McGrath S, Okines A, Parton M, Johnston S, Allen M, Ring A. Safety and efficacy of T-DM1 in patients with advanced HER2-positive breast cancer The Royal Marsden experience. Cancer Treat Res Commun. 2020; 24:100188.

View in: PubMed
Thomas A, Rhoads A, Suhl J, Conway KM, Hundley WG, McNally LR, Oleson J, Melin SA, Lynch CF, Romitti PA. Incidence and Survival by Human Epidermal Growth Factor Receptor 2 Status in Young Women With Stage I-III Breast Cancer: SEER, 2010-2016. Clin Breast Cancer. 2020 08; 20(4):e410-e422.

View in: PubMed
Gargano SM, Senarathne W, Feldman R, Florento E, Stafford P, Swensen J, Vranic S, Gatalica Z. Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling. Cancer Med. 2019 12; 8(17):7322-7329.

View in: PubMed
Freedman RA, Gelman RS, Agar NYR, Santagata S, Randall EC, Gimenez-Cassina Lopez B, Connolly RM, Dunn IF, Van Poznak CH, Anders CK, Melisko ME, Silvestri K, Cotter CM, Componeschi KP, Marte JM, Moy B, Blackwell KL, Puhalla SL, Ibrahim N, Moynihan TJ, Nangia J, Tung N, Burns R, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU. Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022. Clin Breast Cancer. 2020 04; 20(2):145-151.e2.

View in: PubMed
Garcia-Flores AE, Sollome JJ, Thavathiru E, Bower JL, Vaillancourt RR. HER2/HER3 regulates lactate secretion and expression of lactate receptor mRNA through the MAP3K4 associated protein GIT1. Sci Rep. 2019 07 25; 9(1):10823.

View in: PubMed

People

Explore

Similar Concepts

Top Journals